
The mechanistic target of rapamycin (mTOR) is a major signaling intermediary that coordinates favorable environmental conditions with cell growth. Indeed, as part of two functionally distinct protein complexes, named mTORC1 and mTORC2, mTOR regulates a variety of cellular processes, including protein, lipid, and nucleotide synthesis, as well as autophagy. Over the last two decades, major molecular advances have been made in mTOR signaling and have revealed the complexity of the events implicated in mTOR function and regulation. In parallel, the role of mTOR in diverse pathological conditions has also been identified, including in cancer, hamartoma, neurological, and metabolic diseases. Through a series of articles, this book focuses on the role played by mTOR in cellular processes, metabolism in particular, and highlights a panel of human diseases for which mTOR inhibition provides or might provide benefits. It also addresses future studies needed to further characterize the role of mTOR in selected disorders, which will help design novel therapeutic approaches. It is therefore intended for everyone who has an interest in mTOR biology and its application in human pathologies.
Efnisorð
primary cilia neurodegeneration nutrient sensor PI3K transcriptomics phosphorylation metabolic reprogramming autophagy Alzheimer's disease rapalogs liver angiogenesis mTOR complex MBSCs advanced biliary tract cancers Medulloblastoma epithelial to mesenchymal transition AMPK p70S6K lipid metabolism thyroid cancer sodium iodide symporter (NIS)/SLC5A5 male fertility anesthesia illumina mTOR inhibitor miRNA Hutchinson-Gilford progeria syndrome (HGPS) eIFs Emery-Dreifuss muscular dystrophy (EDMD) glucose AKT oral cavity squamous cell carcinoma (OSCC) glucose and lipid metabolism cellular signaling aging tumor microenvironment rapamycin leukemia chloral hydrate rapalogues schizophrenia T-cell acute lymphoblastic leukemia senescence lamin A/C neurotoxicity neurodevelopment inhibitor methamphetamine pulmonary fibrosis mTOR mTOR inhibitors combination therapy proteolysis fluid shear stress tumour cachexia biomarkers synapse gluconeogenesis mTOR signal pathway Sertoli cells immunosenescence miRNome protein aggregation senolytics metabolism NGS mTORC2 mTORC1 metabolic diseases IonTorrent apoptosis dopamine receptor nocodazole microenvironment everolimus acute myeloid leukemia immunotherapy spermatogenesis bone remodeling signalling targeted therapy ageing therapy NVP-BEZ235 fructose physical activity laminopathies MC3T3-E1 cells cell signaling microRNA cancer lipolysis melatonin Parkinson's disease